<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Duex J</submitter><funding>NCI NIH HHS</funding><pagination>1195</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10969618</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(6)</volume><pubmed_abstract>The glycoprotein CD44, with its many isoforms and variations in carbohydrate patterning, participates in a diverse set of cellular functions. This fact leads to the protein playing a role in many normal and pathologic cellular processes including a role in cancer progression and metastasis. These same facts make CD44 a strong therapeutic target in many cancer types, including bladder cancer.</pubmed_abstract><journal>Cancers</journal><pubmed_title>CD44 in Bladder Cancer.</pubmed_title><pmcid>PMC10969618</pmcid><funding_grant_id>R01-CA75115</funding_grant_id><pubmed_authors>Theodorescu D</pubmed_authors><pubmed_authors>Duex J</pubmed_authors></additional><is_claimable>false</is_claimable><name>CD44 in Bladder Cancer.</name><description>The glycoprotein CD44, with its many isoforms and variations in carbohydrate patterning, participates in a diverse set of cellular functions. This fact leads to the protein playing a role in many normal and pathologic cellular processes including a role in cancer progression and metastasis. These same facts make CD44 a strong therapeutic target in many cancer types, including bladder cancer.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2025-04-21T21:27:54.119Z</modification><creation>2025-04-05T18:24:48.983Z</creation></dates><accession>S-EPMC10969618</accession><cross_references><pubmed>38539529</pubmed><doi>10.3390/cancers16061195</doi></cross_references></HashMap>